

Announcement on Completion of Issue of New Shares through Third-Party Allotment

June 30 2017

Rena Therapeutics Inc.

Rena Therapeutics Inc. (Headquarter: Tokyo, Japan, President: Jun Sasaki, hereinafter “Rena Therapeutics”) announce on completion of new shares issue through third-party allotment which total 600M Japanese Yen to NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Japan, President: Yujiro Goto, hereinafter “Nippon Shokubai”), Innovation Network Corporation of Japan, President: Mikihide Katsumata, KSP Inc., President: Hirohisa Uchida.

Rena Therapeutics develops Hetero Duplex Oligonucleotide(HDO) technology, which co-invented by Professor Takanori Yokota of Tokyo Medical and Dental University and Professor Satoshi Obika of Osaka University, to enable as a platform applicable for drug discovery, and expedite making nucleic-acid drugs practical.

Nucleic-acid drugs have been gathering attention as the next generation drug for treating intractable diseases, however, various issues have been revealed and widely known as poor intra-transportation, low blood stability and side-effects.

Hetero Duplex Oligonucleotide (HDO) technology is to utilize double stranded DNA/RNA structure which DNA for medical effect and RNA with ligand molecule for proper drug delivery (Figure) for overcome these issues.



Rena Therapeutics receives fees for HDO technology services with solutions from multiple pharmaceutical companies. As a result of the original research by the first funding, Rena Therapeutics has engaged in two contracts with Japanese Mega-Pharma since the foundation in January 2015.

Rena Therapeutics plans to increase numbers of contract projects with Pharma by accelerating research and reinforcing the HDO technology which consequence to a robust



business bases.

Rena Therapeutics and Nippon Shokubai will engage a research collaboration of HDO technology development, API production technology etc.

Rena Therapeutics continually challenge and support drug discovery for unmet medical needs.

Foundation : January 2015

Capital : 330million Japanese Yen

President : Jun Sasaki

Address : 2-3-10, Kanda-Surugadai Chiyoda-ku Tokyo Japan

HP : http://www.renatherapeutics.com/index_j.html

Contact:

Rena Therapeutics Inc.

TEL : +81 3-5577-3285

Email: info@renatherapeutics.com